Glimser 1 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 1 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization. This dual mechanism addresses both insulin deficiency and insulin resistance, providing effective glycemic control. Glimser 1 Tablet PR is typically prescribed when diet, exercise, and monotherapy with either agent alone are insufficient to achieve target blood glucose levels. It should be administered with meals to minimize gastrointestinal side effects commonly associated with Metformin, such as nausea and diarrhea. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoxia, as these may increase the risk of lactic acidosis. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy. Glimser 1 Tablet PR should be used under medical supervision, with dose adjustments based on therapeutic response and tolerability to optimize diabetes management and reduce the risk of long-term complications.